-
Contributors
-
TwentyTwentyTweets
- @mellojonny so 20 yrs I spent working with elderly/housebound as independent contractor makes me anti-NHS. I can debate - you can't reason! 2 days ago
- @mellojonny @drwollastonmp "an evening panel discussion: should we abolish the NHS" - why would we discuss it if everyone agreed? 2 days ago
- @drwollastonmp #NHS it's a debate not a conference and @2020health is against the motion; is @mellojonny against free speech and debate? 2 days ago
-
Recent Posts
Pages
Author Archives: Barbara Arzymanow
Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines
The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research
Tagged 2020health, Alzheimer's Disease, Andrew Dillon, Andrew lansley, Department of Health, Drugs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, patient access, Patients, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: NHS Reforms- What the UK Government Policy Changes Really Mean
There is a strong consensus amongst independent experts, medical professionals and politicians that major NHS reforms are both desirable and inevitable. Healthcare is one of mankind’s greatest priorities. An aging population and medical advances mean that healthcare expenditure is bound … Continue reading
Posted in Andrew Lansley, Business, competition, David Cameron, Department of Health, Drugs, Elderly, GPs, Health Bill, Hospitals, NHS, Policy, Research, White Paper
Tagged 2020health, Andrew lansley, cherry picking, Commissioning, competition, David Cameron, Department of Health, elderly, GP, GPs, health, Health and Social Care Bill, Health Bill, Ipsos MORI, National Health Service, NHS, NHS Reforms, Patients, pricing, Quality, R&D, Research
Leave a comment
Guest Blogspot – The UK Needs More Biotechnology Companies
The success of US biotechnology companies contrasts sharply with the disappointment in other countries. British companies valued by stock markets at more than about US $ 4 billion go in the FTSE 100 index. There are no biotechnology companies big … Continue reading
Posted in Business, Drugs, Emerging technologies, Finance, Genetics, Pharma, Policy, Research, Technology
Tagged 2020health, Amgen, biotechnology, biotechnology company, block-buster, blockbuster, BTG, drug pricing, Genentech, genetics, medicine, Nobel Prize, patent box, pharmaceutical, pricing, R&D, R&D tax credit, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot- The Future of Pharmaceutical R&D
The productivity of global pharmaceutical R&D has been in a gently declining trend since around 1990. In other words fewer important new medicines have been discovered relative to R&D spending. Many commentators are now saying that the golden era of … Continue reading
Posted in Business, competition, Drugs, Emerging technologies, Finance, Innovation, Pharma, Policy, Research, Technology
Tagged competition, innovation, pharmaceutical, pricing, R&D, Research
Leave a comment
Guest Blogspot- Dept. of Health Consultation on Drug Pricing: “A new value-based approach to the pricing of branded medicines”
The Department of Health deadline for public submissions on pharmaceutical pricing is this Thursday. Many pitfalls must be avoided if the Government’s proposals are to form the basis of a successful drug pricing policy. Some problems are not easy to … Continue reading
Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, NHS, Pharma, Policy, Research, Uncategorized
Tagged 2020health, Andrew lansley, competition, David Jack, Department of Health, Drugs, health, innovation, innovative, medicine, National Health Service, NHS, parallel export, parallel import, patent box, pharmaceutical, PPRS, pricing, R&D, R&D tax credit, Research, unmet, unmet clinical need, unmet healthcare need, unmet medical need, value-based, value-based pricing, winner takes all
1 Comment
Guest Blogspote: How to encourage pharmaceutical R&D
Politicians should only attempt the possible. We must recognise what we cannot do. The UK Government alone cannot influence the direction of R&D significantly. The sums of money involved are so vast that R&D only makes sense in a global … Continue reading
Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, Health Bill, Hospitals, Innovation, NHS, Pharma, Policy, Research, Uncategorized, White Paper
Tagged 2020health, Andrew lansley, biotechnology, breakthrough, Clinical trials, competition, Department of Health, Equity and Excellence, health, Health Bill, medicine, National Health Service, NHS, NICE, patent box, Pfizer, pharmaceutical, pricing, R&D, R&D tax credit, Research, university, value-based, value-based pricing, wholesaler
Leave a comment
Guest Blogspot – NHS Reforms: Health and Social Care Bill 2011
This blog gives my initial thoughts about the eagerly awaited bill presented by Andrew Lansley on Wednesday 19th January. The Government’s plans for the reform of the NHS were generally well received last summer and during the public consultation period … Continue reading
Posted in Andrew Lansley, Department of Health, Drugs, GPs, Health Bill, Inequality, NHS, Pharma, Policy, Primary Care, Research, Technology, Uncategorized, White Paper
Tagged 2020health, Andrew lansley, BMA, Commissioning, Department of Health, Drugs, Equity and Excellence, GP, GPs, health, Health Bill, medicine, NHS, NICE, Responsibility in healthcare, work
Leave a comment
Guest BlogSpot – Which Drugs are the Most Innovative?
Andrew Lansley has recently said: “I am determined that not only will we have a reimbursement price for medicines which reflects their benefit to patients, but also one which incentivises for innovation, and supports those new medicines which respond to … Continue reading
Posted in Andrew Lansley, Department of Health, Drugs, Emerging technologies, NHS, Policy, Research, Technology, Uncategorized
Tagged 2020health, breakthrough, Department of Health, drug pricing, Drugs, health, innovation, innovative, medicine, outcomes, patient, pharmaceutical, R & D, reimbursement, Research, unmet clinical need, unmet healthcare need, value-based pricing
Leave a comment
Guest BlogSpot – Nice Move on Drug Pricing but Where Next?
The Government is reported to favour a system of value-based drug pricing. Value for money is, of course, important whenever public money is spent on anything. Pharmaceuticals are no exception. Discussion about how to obtain the best value from NHS … Continue reading
Posted in Department of Health, Drugs, GPs, Inequality, NHS, Pharma, Policy, Uncategorized, White Paper
Tagged 2020health, Department of Health, Drugs, GPs, health, NHS, NICE, postal lottery, PPRS, prescribing, pricing, value-based
Leave a comment
Liberating the NHS Revisited
The first wave of formal public consultation following last July’s publication of the White Paper “Equity and Excellence: Liberating the NHS” ended over a week ago. Now should be a good time to take stock and reconsider our first impressions. … Continue reading
Posted in Department of Health, Drugs, GPs, Hospitals, Pharma, Policy, Research, White Paper
Leave a comment
